NeuroMetrix (NASDAQ:NURO) Stock Price Crosses Above 200 Day Moving Average – Time to Sell?

NeuroMetrix, Inc. (NASDAQ:NURO) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.14 and traded as high as $4.52. NeuroMetrix shares last traded at $4.50, with a volume of 1,206 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of NeuroMetrix in a report on Friday. They set a “sell” rating for the company.

NeuroMetrix Trading Down 1.8 %

The firm has a market capitalization of $9.09 million, a price-to-earnings ratio of -0.97 and a beta of 2.15. The stock has a fifty day moving average of $4.35 and a 200-day moving average of $4.14.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NeuroMetrix stock. GTS Securities LLC acquired a new position in NeuroMetrix, Inc. (NASDAQ:NURO) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 22,759 shares of the medical device company’s stock, valued at approximately $90,000. GTS Securities LLC owned 1.12% of NeuroMetrix as of its most recent filing with the SEC. Institutional investors and hedge funds own 19.40% of the company’s stock.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.